In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library

In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library

Neutralizing antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and/or treat COVID-19. However, as SARS-CoV-2 has evolved into new variants, most of the neutralizing antibodies authorized by the US FDA and/or EMA to treat COVID-19...

Full description

Bibliographic Details
Main Authors: Edith González-González, Gregorio Carballo-Uicab, Juana Salinas-Trujano, María I. Cortés-Paniagua, Said Vázquez-Leyva, Luis Vallejo-Castillo, Ivette Mendoza-Salazar, Keyla Gómez-Castellano, Sonia M. Pérez-Tapia, Juan C. Almagro
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Antibodies
Subjects:
COVID-19
broadly neutralizing antibody
non-clinical efficacy
Delta variant
Omicron variant
Online Access:https://www.mdpi.com/2073-4468/11/3/57

Internet

https://www.mdpi.com/2073-4468/11/3/57

Similar Items